Novel and promising designs of ADC - Bispecific ADCs (BsADCs) The main source of ADC toxicity is the non-specific binding of antibodies to antigens. 2 Improving the selectivity and specificity of ...

By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

To gain a better understanding of the data on ADC combinations in aUC ... a high chance of encountering things like hematological toxicity, neutropenia or anemia may require more frequent blood ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen ... of ImmunoGen's payload technologies, the toxic molecules that add a cell-killing ...

Background: ImmunoGen’s Patent Application & Dispute - In 2014, ImmunoGen, Inc. (Immunogen) filed U.S. Patent Application ...

BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1 ... targeting dual epitopes of ROR1 with the small-molecule toxin eribulin. It is the world's first anti-ROR1 Bi-paratopic ...

Akeso is dedicated to transforming the global oncology treatment landscape by establishing new standards of care for cancer patients worldwide. A key element of this mission is the company's "IO 2.0 + ...

reducing the risk of off-target toxicity. As CDH17 is an abundantly expressed and rapidly internalizing transmembrane protein on GI cancer cells, CDH17 is ideally suited for an ADC-mediated drug ...

Akeso begins patient enrolment in phase I trial of AK138 D1 for the treatment of advanced malignancies in Australia: Hong Kong Saturday, March 1, 2025, 12:00 Hrs [IST] Akeso, Inc.